AMEX
Nasus Pharma Ltd. Ordinary Shares (NSRX)
♥ 692 Thanks from members
Nasus Pharma Ltd. (NSRX) garners a mixed-to-cautious market sentiment, supported by positive Phase 2 clinical results for its lead intranasal epinephrine candidate NS002 and a recent $15 million private placement, but heavily tempered by going concern disclosures, cash runway limits, and historical net losses.